MedTrace Logo

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

NCT05904379 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2026-03-09

No results posted yet for this study

Summary

This trial is a Phase Ib/II study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and AK104 with or without chemotherapy in subjects with advanced NSCLC.

Conditions

  • Advanced Non-small-cell Lung Cancer

Interventions

DRUG

AK112

Subjects receive AK112 intravenously.

DRUG

AK104

Subjects receive AK104 intravenously.

DRUG

Carboplatin

Subjects receive carboplatin intravenously.

DRUG

paclitaxel

Subjects receive paclitaxel intravenously.

DRUG

pemetrexed

Subjects receive pemetrexed intravenously.

DRUG

Docetaxel

Subjects receive docetaxel intravenously.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-13
Primary Completion
2026-06-30
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05904379 on ClinicalTrials.gov